tbuckley/cabot-search huggingface dataset:
Efficacy of vitamin D3 supplementation on cancer mortality: Systematic review and individual patient data meta-analysis of randomised controlled trials
Authors: Sabine Kuznia, Anna Zhu, Taisuke Akutsu, Julie E. Buring, Carlos A. Camargo Jr, Nancy R. Cook, Li-Ju Chen, Ting-Yuan David Cheng, Sari Hantunen, I.-Min Lee, JoAnn E. Manson, Rachel E. Neale, Robert Scragg, Aladdin H. Shadyab, Sha Sha, John Sluyter, Tomi-Pekka Tuomainen, Mitsuyoshi Urashima, Jyrki K. Virtanen, Ari Voutilainen, Jean Wactawski-Wende, Mary Waterhouse, Hermann Brenner, Ben Schöttker
Journal: Ageing Research Reviews (2023)
Argyrophilic grain disease is common in older adults and may be a risk factor for suicide: a study of Japanese forensic autopsy cases
Authors: Koji Yoshida, Yukiko Hata, Shojiro Ichimata, Keitaro Okada, Naoki Nishida
Journal: Translational Neurodegeneration (2023)

Neuropathological diagnosis of argyrophilic grain disease (AGD) is currently based primarily on the combination of argyrophilic grain (AG) visualized using Gallyas-Braak silver staining, phosphorylated tau-positive pretangles, coiled bodies, and ballooned neuron detection. Although AGD is common in patients with dementia and/or prominent psychiatric symptoms, whether it is a distinct neurological disease entity or a by-product of the aging process remains unclear.In 1449 serial forensic autopsy cases > 40 years old (823 males and 525 females, aged 40-101 years, mean age 70.0 ± 14.1 years), we examined the frequency and comorbid pathology of AGD cases and investigated the clinical appearance by comparing those with non-AGD cases using the propensity score.Of the 1449 cases, we detected 342 AGD cases (23.6%; mean age 79.7 years; 177 males and 165 females). The AGD frequency and stage increased with age (P < 0.001). Among AGD cases, 80 (23.4%) patients had dementia, and 51 (15.2%) had a history of psychiatric hospital visits. The frequency of suicide and history of psychiatric disorders were significantly higher in AGD cases than in AGD-negative cases, matched for age, sex, and comorbidity pathology, with a relative risk of suicide of 1.72 (1.30-2.26). The frequency of suicide was significantly higher in AGD cases than in non-AGD cases in female but not male cases. The relative risk of suicide increased to 2.27 (1.20-4.30) and 6.50 (1.58-26.76) in AGD patients with Lewy and progressive supranuclear palsy pathology, respectively, and decreased to 0.88 (0.38-2.10) in those with advanced AD pathology. In AGD cases, 23.4% had dementia; however, the difference was not significant after controlling for age, sex, and comorbid pathology.Our study demonstrated that AGD is a significant and isolated risk factor for psychiatric hospital visits and suicide completion. In older adults, AGs may contribute to the progression of functional impairment of the limbic system, which leads to psychiatric disorders and suicide attempts.
HSR23-120: Real-World Observations Show Beneficial Outcomes in Patients With NSCLC Treated With Pembrolizumab for More Than 2 Years
Authors: Lucio Gordan, Rushir Choksi, Daniel Petro, Melissa Johnson, Anupama Vasudevan, Sandy English, Marielle Fares, Heidi Gidley, Teena Sura, Prateesh Varughese
Journal: Journal of the National Comprehensive Cancer Network (2023)
QIM23-131: A Retrospective Review of Myelodysplastic Syndrome Management (MDS) at Watson Clinic LLP: From Diagnosis to Primary Course of Treatment
Authors: Shane Burke, Galina Vugman, Noreen McGowan, Michelle Sharrett
Journal: Journal of the National Comprehensive Cancer Network (2023)

"QIM23-131: A Retrospective Review of Myelodysplastic Syndrome Management (MDS) at Watson Clinic LLP: From Diagnosis to Primary Course of Treatment" published on 31 Mar 2023 by National Comprehensive Cancer Network.
Clinical consensus guideline on the management of phaeochromocytoma and paraganglioma in patients harbouring germline SDHD pathogenic variants
Authors: David Taïeb, George B Wanna, Maleeha Ahmad, Charlotte Lussey-Lepoutre, Nancy D Perrier, Svenja Nölting, Laurence Amar, Henri J L M Timmers, Zachary G Schwam, Anthony L Estrera, Michael Lim, Erqi Liu Pollom, Lucas Vitzthum, Isabelle Bourdeau, Ruth T Casey, Frédéric Castinetti, Roderick Clifton-Bligh, Eleonora P M Corssmit, Ronald R de Krijger, Jaydira Del Rivero, Graeme Eisenhofer, Hans K Ghayee, Anne-Paule Gimenez-Roqueplo, Ashley Grossman, Alessio Imperiale, Jeroen C Jansen, Abhishek Jha, Michiel N Kerstens, Henricus P M Kunst, James K Liu, Eamonn R Maher, Daniele Marchioni, Leilani B Mercado-Asis, Ozgur Mete, Mitsuhide Naruse, Naris Nilubol, Neeta Pandit-Taskar, Frédéric Sebag, Akiyo Tanabe, Jiri Widimsky, Leah Meuter, Jacques W M Lenders, Karel Pacak
Journal: The Lancet Diabetes & Endocrinology (2023)
YIA23-004: Non-Melanoma Skin Cancer (NMSC) in Patients With Chronic Lymphocytic Leukemia (CLL): Biology and Prevention
Authors: Deborah M. Stephens, Kenneth Boucher, David A. Wada, Aaron Atkinson, Jack Abbott, Marianne Bowling, Justin Williams, Anthony D. Pomicter, Renee Vadeboncouer, Clayton Savage, Brynn Parsegov, Lindsey Gilstrap, Christa Shorter, Harsh Shah, Boyu Hu, Lindsey Fitzgerald
Journal: Journal of the National Comprehensive Cancer Network (2023)
HSR23-114: Clinical Characteristics and Outcomes of US Extensive Stage Small Cell Lung Cancer (ES-SCLC) Patients Not Receiving Guideline Preferred Regimens
Authors: Daniel Simmons, Yang Xiao, Corina Roca, Zhuoxin Jiang, Marnie Boron
Journal: Journal of the National Comprehensive Cancer Network (2023)

"HSR23-114: Clinical Characteristics and Outcomes of US Extensive Stage Small Cell Lung Cancer (ES-SCLC) Patients Not Receiving Guideline Preferred Regimens" published on 31 Mar 2023 by National Comprehensive Cancer Network.
HSR23-112: Disease Burden and Treatment Patterns in Patients Diagnosed With HER2- Metastatic Gastric/Gastroesophageal Junction Cancer (mG/GEJC)
Authors: Rutika Mehta, Rupali Fuldeore, Hongbo Yang, Wei Song, Adina Zhang, Sophie Gao, Christopher Young, Bin Xie
Journal: Journal of the National Comprehensive Cancer Network (2023)

"HSR23-112: Disease Burden and Treatment Patterns in Patients Diagnosed With HER2- Metastatic Gastric/Gastroesophageal Junction Cancer (mG/GEJC)" published on 31 Mar 2023 by National Comprehensive Cancer Network.
HSR23-117: First-Line (1L) Systemic Therapy in Patients (pts) With Advanced Non–Small Cell Lung Cancer (aNSCLC) at Community Settings in the United States (US)
Authors: Stephen Liu, Pragya Rai, Yu-Han Kao, Diana Chirovsky, Ana Nunes
Journal: Journal of the National Comprehensive Cancer Network (2023)

"HSR23-117: First-Line (1L) Systemic Therapy in Patients (pts) With Advanced Non–Small Cell Lung Cancer (aNSCLC) at Community Settings in the United States (US)" published on 31 Mar 2023 by National Comprehensive Cancer Network.
HSR23-116: Emotional and Mental Health Support Needs of Adolescent and Young Adult (AYA) Colorectal Cancer Patients
Authors: Kimberly P. Rogers, Victoria G. Morris, Erica E. Fortune, Andrea Goodman, Kim Newcomer, M. Susan Pfau, Christine L. Sardo Molmenti, Cynthia A. Thomson, Alan P. Venook, Melissa F. Miller
Journal: Journal of the National Comprehensive Cancer Network (2023)
EPR23-083: Non-Squamous, Metastatic Non–Small Cell Lung Cancer: Retrospective c-Met Overexpression Testing, Patient Characteristics, and Treatment Patterns
Authors: Mona H. Cai, Yookyung Christy Choi, Athan Vasilopoulos, Alexander Liede, Sidney S. Lindsey, Leon Raskin, Ethan Truong, Jeremy Fricke, Stephen B. Gruber, Peter J. Ansell
Journal: Journal of the National Comprehensive Cancer Network (2023)

"EPR23-083: Non-Squamous, Metastatic Non–Small Cell Lung Cancer: Retrospective c-Met Overexpression Testing, Patient Characteristics, and Treatment Patterns" published on 31 Mar 2023 by National Comprehensive Cancer Network.
HSR23-101: Characteristics and Outcomes of Patients Treated With Selpercatinib in the Real-World: A Retrospective Study Using US Claims Databases
Authors: Naleen Raj Bhandari, Neha Bansal, Chi-Wei Duann, Anasofia Afonso, Shen Zheng
Journal: Journal of the National Comprehensive Cancer Network (2023)

"HSR23-101: Characteristics and Outcomes of Patients Treated With Selpercatinib in the Real-World: A Retrospective Study Using US Claims Databases" published on 31 Mar 2023 by National Comprehensive Cancer Network.
HSR23-107: Real-World Study of Biomarker Testing and Treatment Patterns in Patients With Metastatic Castration-Resistant Prostate Cancer in the United States (US): A Physician Survey
Authors: Sabine Oskar, Jeri Kim, Alicia Gayle, Chloe Middleton-Dalby, Himani Aggarwal
Journal: Journal of the National Comprehensive Cancer Network (2023)

"HSR23-107: Real-World Study of Biomarker Testing and Treatment Patterns in Patients With Metastatic Castration-Resistant Prostate Cancer in the United States (US): A Physician Survey" published on 31 Mar 2023 by National Comprehensive Cancer Network.
QIM23-145: Dosimetric Assessment of 3-Dimensions Radiotherapy (3D-RT) and Intensity Modulated Radiotherapy (IMRT) for Flank Irradiation in Pediatric Patients With Wilms’ Tumor: Benefit-Risk Balance
Authors: Rym Zanzouri, Nadia Bouzid, Mohamed Souissi, Bawader Amri, Raouf Hammouda, Syrine Ben Dhia, Sabrine Tbessi, Samia Kanoun Belajouza, Sameh Tebra
Journal: Journal of the National Comprehensive Cancer Network (2023)

"QIM23-145: Dosimetric Assessment of 3-Dimensions Radiotherapy (3D-RT) and Intensity Modulated Radiotherapy (IMRT) for Flank Irradiation in Pediatric Patients With Wilms’ Tumor: Benefit-Risk Balance" published on 31 Mar 2023 by National Comprehensive Cancer Network.
HSR23-119: Real-World Duration of Venetoclax Treatment for Chronic Lymphocytic Leukemia and Small Lymphocytic Leukemia (CLL/SLL)
Authors: Anna Teschemaker, Shweta Hakre, Jenny Tse, Nazneen Fatima Shaikh, Yifan Gu, Aimee Near
Journal: Journal of the National Comprehensive Cancer Network (2023)
HSR23-092: Real-World Analysis Examining Cost of Early Disease Progression Among Patients With Epidermal Growth Factor Receptor Mutated Metastatic Non–Small Cell Lung Cancer
Authors: Nicole Princic, Elizabeth Marrett, Winghan Jacqueline Kwong, Donna McMorrow, Hana Schwartz, Janakiraman Subramanian
Journal: Journal of the National Comprehensive Cancer Network (2023)

"HSR23-092: Real-World Analysis Examining Cost of Early Disease Progression Among Patients With Epidermal Growth Factor Receptor Mutated Metastatic Non–Small Cell Lung Cancer" published on 31 Mar 2023 by National Comprehensive Cancer Network.
Association Between Preoperative Diabetes Control and Postoperative Adverse Events Among Veterans Health Administration Patients With Diabetes Who Underwent Elective Ambulatory Hernia Surgery
Authors: Jessica Shanahan, Varsha G. Vimalananda, Laura Graham, Roman Schumann, Hillary J. Mull
Journal: JAMA Network Open (2023)

This cohort study examines the association between same-day preoperative glycemic control and postoperative adverse events among patients with diabetes undergoing ambulatory hernia surgery.
Self-assembly of CXCR4 antagonist peptide–docetaxel conjugates for breast tumor multi-organ metastasis inhibition
Authors: Chen Li, Jiayan Lang, Yazhou Wang, Zhaoxia Cheng, Mali Zu, Fenfen Li, Jingyi Sun, Yating Deng, Tianjiao Ji, Guangjun Nie, Ying Zhao
Journal: Acta Pharmaceutica Sinica B (2023)

As a representative chemotherapeutic drug, docetaxel (DTX) has been used for breast cancer treatment for decades. However, the poor solubility of DTX limits its efficacy, and the DTX based therapy increases the metastasis risk due to the upregulation of C–X–C chemokine receptor type 4 (CXCR4) expression during the treatment. Herein, we conjugated CXCR4 antagonist peptide (CTCE) with DTX (termed CTCE–DTX) as an anti-metastasis agent to treat breast cancer. CTCE–DTX could self-assemble to nanoparticles, targeting CXCR4-upregulated metastatic tumor cells and enhancing the DTX efficacy. Thus, the CTCE–DTX NPs achieved promising efficacy on inhibiting both bone-specific metastasis and lung metastasis of triple-negative breast cancer. Our work provided a rational strategy on designing peptide–drug conjugates with synergistic anti-tumor efficacy.
Programmed Cell Death Ligand 1 Expression on Immune Cells and Survival in Patients With Nonmetastatic Head and Neck Cancer
Authors: Tomáš Blažek, Marek Petráš, Lukáš Knybel, Jakub Cvek, Renata Soumarová
Journal: JAMA Network Open (2023)

Importance The failure or success of radical treatment in patients with head and neck squamous cell carcinoma (HNSCC) is associated with many known and unknown factors; hence, there is a search for further prognostic markers to help optimize therapeutic strategy and improve treatment outcomes. Objective To assess the association of programmed cell death ligand 1 (PD-L1) expression on immune or tumor cells, including its composite expression on both cell types, with overall survival (OS) or specific survival. Data Sources MEDLINE, Embase, PQSciTech, and HCAPlus databases were systematically searched for cohort studies focused on the prognostic role of PD-L1 expression in patients with HNSCC in curative stages of the disease. Search results generated publications from January 1, 2010, to January 6, 2023. Study Selection Of 3825 publications identified, a total of 17 cohort studies in the English language met inclusion criteria of this systematic review and meta-analysis. Eligible studies reported adjusted hazard ratios (aHRs) with 95% CIs for the association of PD-L1 expression levels with OS and arbitrary specific survival. Data Extraction and Synthesis Data from studies were extracted independently by 2 researchers strictly adhering to the Preferred Reporting Items for Systematic Reviews and Meta-analyses reporting guidelines and recommendations. The risk of bias was assessed using the Quality in Prognosis Studies tool and Newcastle-Ottawa Scale. Pooled effect estimates were obtained using a random-effect or fixed-effect model based on homogeneity of studies. Main Outcomes and Measures The primary outcome was to investigate whether there was an association between PD-L1 expression on immune or tumor cells and OS. Results In 17 cohort studies of the association of PD-L1 expression with survival in 3190 patients with HNSCC, high PD-L1 expression on immune cells was associated with a favorable OS (pooled aHR, 0.39; 95% CI, 0.25-0.59). There was no association between composite PD-L1 expression on immune and tumor cells and OS (pooled aHR, 0.79; 95% CI, 0.55-1.14) or between PD-L1 expressed only on tumor cells and OS (pooled aHR, 1.22; 95% CI, 0.87-1.70). A high level of PD-L1 expression on immune cells was associated with favorable specific survival (pooled aHR, 0.52; 95% CI, 0.38-0.72). There were no interactions between tumor location or type of primary treatment (ie, surgery vs radiotherapy or radiochemotherapy) and the association between PD-L1 expression and OS. Conclusions and Relevance This study’s findings suggest that PD-L1 expression on immune cells may serve as a new prognostic biomarker in patients with HNSCC. However, future studies may be warranted to verify this potential role given the limited number of studies on this topic conducted and published to date.
QIM23-146: Using a Multi-Modal Approach in Addressing Identified Barriers to Improve Lung Cancer Screening in Northeast Georgia—An Interim Report
Authors: Swathi Kanakamedala, Andria Caton, Shivang Umesh Danak
Journal: Journal of the National Comprehensive Cancer Network (2023)

"QIM23-146: Using a Multi-Modal Approach in Addressing Identified Barriers to Improve Lung Cancer Screening in Northeast Georgia—An Interim Report" published on 31 Mar 2023 by National Comprehensive Cancer Network.
Bone mesenchymal stem cell-derived exosomes involved co-delivery and synergism effect with icariin via mussel-inspired multifunctional hydrogel for cartilage protection
Authors: Jia Zeng, Peng Sun, Yuanqian Zhao, Xinning Fang, Zhenghong Wu, Xiaole Qi
Journal: Asian Journal of Pharmaceutical Sciences (2023)

Mesenchymal stem cells (MSC) are particularly effective in promoting cartilage regeneration due to their immunomodulatory, anti-inflammatory and regenerative repair functions of tissues and organs. Meanwhile, the intra-articular delivery and synergy with other therapeutic drugs have been the key issues driving their further application. We report a mussel-inspired multifunctional hydrogel system, which could achieve co-delivery and synergism effect of MSC-derived exosomes (Exos) with icariin (ICA). The ICA and Exos co-delivered articular cavity injection system are expected to retain in the joint cavity and promote cartilage regeneration, due to the thermosensitive, self-healing and adhesion properties of the mussel-inspired multifunctional hydrogel. The experimental results proved that Exos enhanced the cellular uptake of ICA by more than 2-fold evenly, and the synergism of Exos and ICA efficiently improve the cell proliferation and migration. After synergic treatment, the content of matrix metalloproteinase 13 in the supernatant and intracellular decreased by 47% and 59%, respectively. In vivo study, ICA-loaded Exos exhibited prolonged retention behavior by multifunctional hydrogel delivery, thus displayed an increased cartilage protection. In the model of osteoarthritis, co-delivery hydrogel system relieved the cartilage recession, ensuring appropriate cartilage thickness.
Transcatheter Arterial Chemoembolization for Treatment-Naive Hepatocellular Carcinoma Has Different Treatment Effects Depending on Central or Peripheral Tumor Location
Authors: Kazuo Asano, Ken Kageyama, Akira Yamamoto, Atsushi Jogo, Sawako Uchida-Kobayashi, Etsuji Sohgawa, Kazuki Murai, Norifumi Kawada, Yukio Miki
Journal: Liver Cancer (2023)

The purpose of this study was to evaluate the treatment efficacy of transcatheter arterial chemoembolization (TACE) for treatment-naive hepatocellular carcinoma (HCC) according to tumor location and burden.Between 2010 and 2019, consecutive patients who underwent TACE as the first treatment were enrolled. Tumors were classified into two categories based on their location, as central or peripheral tumors. Tumors in the central zone, which is within 1 cm of the main trunk or the first branch of the portal vein, were classified as central tumors, while those located in the peripheral zone were classified as peripheral tumors. Patients were grouped according to the HCC location and up-to-7 criteria. Patients with central tumors were classified into the central arm and those with only peripheral tumors were classified into the peripheral arm. Patients within and beyond the up-to-7 criteria were classified into the up-to-7 in and up-to-7 out-groups, respectively. Local recurrence-free survival (LRFS) and progression-free survival (PFS) were compared per nodule (central tumor vs. peripheral tumor) and per patient (central arm vs. peripheral arm), respectively. The prognostic factors of LRFS and PFS were analyzed by univariate and multivariate analyses.A total of 174 treatment-naive patients with 352 HCCs were retrospectively enrolled. Ninety-six patients and 130 lesions were selected by propensity score matching. Median LRFS was longer for peripheral tumors than central tumors (not reached vs. 3.3 months, p < 0.001). Median PFS was 17.1 months (8.3-24.9) in the peripheral arm and up-to-7 in, 7.0 months (3.3-12.7) in the peripheral arm and up-to-7 out, 8.4 months (4.0-12.6) in the central arm and up-to-7 in, and 3.0 months (1.2-4.9) in the central arm and up-to-7 out-groups. The peripheral arm and up-to-7 in-groups had significantly longer PFS than the other three groups (p = 0.013, p = 0.015, p < 0.001, respectively). Multivariate analysis confirmed that the central zone and central arm were associated with high adjusted hazard ratios for tumor recurrence or death (2.87, p < 0.001; 2.89, p < 0.001, respectively).Treatment-naive HCCs in the peripheral zone had a longer LRFS and PFS following TACE compared to those in the central zone.
Corrigendum to “78P Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+ GC) in patients (pts) with advanced biliary tract cancer (BTC)”
Authors: D. Oh, A.R. He, S. Qin, L. Chen, T. Okusaka, A. Vogel, J.W. Kim, T. Suksombooncharoen, M.A. Lee, M. Kitano, H.A. Burris, M. Bouattour, S. Tanasa, R.E. Zaucha, A. Avallone, J.E. Cundom, N. Rokutanda, M. Żotkiewicz, G. Cohen, J.W. Valle
Journal: Annals of Oncology (2023)
Selective JAK1 inhibitors for the treatment of inflammatory bowel disease
Authors: Ole Haagen Nielsen, Theresa Louise Boye, John Gubatan, Deepavali Chakravarti, James B. Jaquith, Eric C. LaCasse
Journal: Pharmacology & Therapeutics (2023)

Janus kinase (JAK) inhibitors, also known as jakinibs, are third-generation oral small molecules that have expanded the therapeutic options for the management of chronic inflammatory diseases, including inflammatory bowel disease (IBD). Tofacitinib, a pan-JAK inhibitor, has spearheaded the new JAK class for IBD treatment. Unfortunately, serious adverse effects, including cardiovascular complications such as pulmonary embolism and venous thromboembolism or even death from any cause, have been reported for tofacitinib. However, it is anticipated that next-generation selective JAK inhibitors may limit the development of serious adverse events, leading to a safer treatment course with these novel targeted therapies. Nevertheless, although this drug class was recently introduced, following the launch of second-generation biologics in the late 1990s, it is breaking new ground and has been shown to efficiently modulate complex cytokine-driven inflammation in both preclinical models and human studies. Herein, we review the clinical opportunities for targeting JAK1 signaling in the pathophysiology of IBD, the biology and chemistry underpinning these target-selective compounds, and their mechanisms of actions. We also discuss the potential for these inhibitors in efforts to balance their benefits and harms.
BPI23-011: Real-World Study of First-Line Treatment Patterns in HR+/HER2– Metastatic Breast Cancer (MBC) at a Tertiary Care Cancer Institute
Authors: Yolcar Chamorro, Manmeet S. Ahluwalia, Muni B. Rubens, Siddhartha A. Venkatappa, Andrew J. Belli, Nicholas Ritter, Ching-Kun Wang, Reshma L. Mahtani, Ana Sandoval Leon
Journal: Journal of the National Comprehensive Cancer Network (2023)

"BPI23-011: Real-World Study of First-Line Treatment Patterns in HR+/HER2– Metastatic Breast Cancer (MBC) at a Tertiary Care Cancer Institute" published on 31 Mar 2023 by National Comprehensive Cancer Network.
<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" altimg="si4.svg" display="inline" id="d1e1133"><mml:mrow><mml:mi>T</mml:mi><mml:mi>r</mml:mi><mml:mi>G</mml:mi><mml:mi>A</mml:mi><mml:mi>N</mml:mi><mml:mi>e</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:math>: Transforming 3T to 7T dMRI using Trapezoidal Rule and Graph based Attention Modules
Authors: Ranjeet Ranjan Jha, B.V. Rathish Kumar, Sudhir K. Pathak, Arnav Bhavsar, Aditya Nigam
Journal: Medical Image Analysis (2023)
CGE23-070: Baseline Neutrophil to Lymphocyte Ratio and Its Change Over Time Predict Overall Survival in Metastatic Non–Small Cell Lung Cancer Patients Who Received First Line Pembrolizumab Therapy
Authors: Kenneth Chian, Mingjia Li, Songzhu Zhao, Saira Farid, Timothy Gauntner, Daniel Spakowicz, Lai Wei, Austin Secor, Evelyn Goodyear, Parthib Das, Kai He, Asrar Alahmadi, Regan Memmott, Jacob Kaufman, Carolyn Presley, Peter Shields, David Carbone, Greg Otterson, Dwight Owen
Journal: Journal of the National Comprehensive Cancer Network (2023)

"CGE23-070: Baseline Neutrophil to Lymphocyte Ratio and Its Change Over Time Predict Overall Survival in Metastatic Non–Small Cell Lung Cancer Patients Who Received First Line Pembrolizumab Therapy" published on 31 Mar 2023 by National Comprehensive Cancer Network.